Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2007 | 79 | 6 | 454-460

Article title

c-erbB-2/HER2/NEU Protein in Breast Cancer - Current State of Knowledge


Title variants

Languages of publication












Physical description


1 - 6 - 2007
27 - 11 - 2007


  • Department of Surgical Oncology Chair of Oncology, Medical University in Łódź


  • Coussens L, Yang-Feng TL, Liao Y-C et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-39.[Crossref]
  • Shih C, Padhy LC, Murray M et al.: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290: 261-64.[Crossref]
  • Van de Geer P, Hunter T, Lindberg RA: Receptor protein-kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10: 251-337.
  • Sliwkowski MX, Lofgren JA, Lewis GD et al.: Nonclinical studiem addressing the mechanism of action of trastuzumab (Herceptin). Sem Oncol 1999; 26: 60-70.
  • Rubin I, Yarden Y: The basic biology of HER2. Ann Oncol 2001; 12: S3-S8.[PubMed][Crossref]
  • Gompel A, Martin A, Simon P et al.: Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle. Breast Cancer Res Treat 1996; 38: 227-35.[Crossref]
  • Pauletti G, Godolphin W, Press MF et al.: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
  • Venter DJ, Tuzi NL, Kumar S et al.: Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification. Lancet 1987; ii: 69-72.
  • Van de Vijver MJ, Peterse JL, Moor WJ et al.: Neuprotein overexpression in breast cancer. Association with comedo-type ductal carcinoma and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319: 1239-45.
  • Fabian CJ, Kimler BF, Zalles CM et al.: Shortterm breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000; 92: 1217-27.[Crossref]
  • Slamon DJ, Clark GM, Wong SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235: 177-82.[Crossref]
  • Goldhirsch A, Glick JH, Gelber RD et al.: Meeting highlights: International Expert Consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-83.[Crossref]
  • Baselga J, Norton L, Albanell J et al.: Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31.
  • Eiermann W, on behalf of the International Her-ceptin Study Group: Trastuzumab combined with chemotherapy for the treatment of HER-positive metastatic breast cancer: Pivotal trial data. Ann Oncol 2001; 12 (Suppl 1): S57-S62.[Crossref]
  • Leyland-Jones B: Trastuzumab: hopes and realities. Lancet Oncol 2003; 3: 137-44.
  • Pietras RJ, Fendly BM, Chazin VR et al.: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 54: 1829-38.
  • Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001; 344: 783-92.[Crossref]
  • Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.[Crossref]
  • Olszewski WT: Status HER2 w raku piersi - informacje praktyczne dla lekarzy. Nowa Medycyna 2005; 126: 4-9.
  • Hayes DF, Thor AD: c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002; 29: 231-45.[Crossref]
  • Taylor SL, Rudland PS, Barraclough R: C-erbB-2 mRNA in breast cancer specimens that exhibit membrane or cytoplasmic immunoreactivity for c-erbB-2. Oncol Res 1999; 11: 311-17.[PubMed]
  • Taylor SL, Platt-Higgins A, Rudland PS et al.: Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. Int J Cancer 1998; 76: 459-63.[Crossref]
  • Rozan S, Vincent-Salomon A, Zafrani B et al.: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79: 27-33.
  • Terrier P, Mouriesse H, Loridon B et al.: Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein over-expression in human breast cancer. Acta Oncologica 1996; 35: 23-30.[Crossref]
  • Schnitt SJ: Breast cancer in 21st century: neu opportunities and neu challenges. Mod Pathol 2001; 14: 213-18.[Crossref][PubMed]
  • Olszewski WT, Krzakowski M: Rekomendacje Polskiej Grupy Badawczej ds. HER2. Nowotwory - Journal of Oncology 2004; 54: 500-05.
  • Jassem J, Krzakowski M, Olszewski W i wsp.: Rak piersi. Zalecenia diagnostyczno-terapeutyczne Polskiej Unii Onkologii. Nowotwory - Journal of Oncology 2003; 53: 300-24.
  • Farabegoli F, Ceccarelli C, Santini D et al.: c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples. Int J Cancer 1999; 84: 273-77.[Crossref]
  • Hynes NE, Stern DF: The biology of erb-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta 1994; 1198: 165-84.
  • Mass RD, Press M, Anderson S et al.: Improved survival benefit form Herceptin (trastuzumab) inpatients selected by fluorescence in situ hybridization (FISH). ASCO 2001; Abstract 85.
  • Pauletti G, Dandekar S, Rong HM et al.: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-64.
  • Tubbs RR, Pettay JD, Roche PC et al.: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19: 2714-21.
  • Riou G, Mathieu MC, Barrois M et al.: c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer 2001; 95: 266-70.[Crossref]
  • Koscielny S, Terrier P, Daver A et al.: Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values. Eur J Cancer 1998; 34: 476-81.[Crossref]
  • Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359-65.[Crossref]
  • Bandyopadhyay D, Redkar A, Bharde S et al.: Prognostic association of c-erbB-2 oncogene amplification and protein overexpression in human breast cancer using archival tissues. Acta Oncologica 1994; 33: 493-98.[Crossref]
  • Goussia A, Agnantis NJ, Athanassiadou S et al.: Prognostic significance of c-erbB-2 and hormone receptors' status in human benign and malignant breast lesions. Anticancer Res 1995; 15: 2313-18.
  • Sjörgen S, Inganäs M, Lindgren A et al.: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462-69.
  • Olszewski WT, Mrozkowiak A, Olszewski WP i wsp.: Ocena populacyjna ekspresji HER2 w raku piersi w Polsce. Nowotwory J Oncol 2003; 53 supl 1: 53.
  • Olszewski WT, Olszewski WP, Mrozkowiak A et al.: HER2 status population screening of breast carcinoma in Poland - immunohistochemical evaluation of 5946 cases. Breast Cancer Res Treat 2003; 82: supl 1: 142-43.
  • Fu W, Lobocki CA, Silberberg BK et al.: Molecular markers in Paget disease of the breast. J Surg Oncol 2001; 77: 171-78.[Crossref][PubMed]
  • Keatings L, Sinclair J, Wright C et al.: c-erbB-2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study. Histopathology 1990; 17: 243-47.[Crossref]
  • Jakić-Razumović J, Petrovecki M, Užarević B et al.: Mutual predictive value of c-erbB-2 overexpression and various prognostic factors in ductal invasive breast carcinoma. Tumori 2000; 86: 30-36.
  • Aziz SA, Pervez S, Khan S et al.: Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis in human breast cancer. Pathol Oncol Res 2001; 7: 190-96.[Crossref]
  • Anbazhagan R, Gelber RD, Bettelheim R et al.: Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 1991; 2: 47-53.
  • Reed W, Hannisdal E, Boehler PJ et al.: The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. Cancer 2000; 88: 804-13.
  • Jeziorski A: Analiza immunologiczna białkowych produktów wybranych onkogenów i genów supresorowych w pierwotnym inwazyjnym raku zrazikowym piersi u kobiet. Akademia Medyczna w Łodzi, Łódź 2000.
  • Acenero FMJ, Gonzales FJ, Ballesteros AP: Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma, relation with epidemiologic factors, histologic features and prognosis. Gen Diagn Pathol 1997; 142: 289-96.
  • Moland JG, Barraclough BH, Gebski V et al.: Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer. Aust N Z J Surg 1996; 66: 64-70.
  • Tetu B, Brisson J, Plante V et al.: p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 1998; 11: 823-30.
  • Trock BJ, Yamauchi H, Brotzman M et al.: cerbB-2 as a prognostic factor in breast cancer: A meta-analysis. Proc Am Soc Clin Oncol 2000; 19: 97a.
  • De Laurentis M, Arpino G, Massarelli E et al.: A metaanalysis of the interaction between Her2 and response to endocrine therapy (ET) in metastatic breast cancer (MBC). ASCO 2000; 19: Abstract 301.
  • Capri G, Mezzlani A, Valagussa P et al.: HER-2/neu (HER2) amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer. ASCO 1997; 16: 139a.
  • Iwase H, Itoh Y, Kuzushima T et al.: Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer. Cancer Detect Prev 1997; 21: 29-35.
  • Baselga J, Perez EA, Pienkowski T et al.: Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006; 11 Suppl 1: 4-12.[Crossref]
  • Smith I, Procter M, Gelber RD et al.: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007; 369: 29-36.

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.